|
| Takeda gets US FDA response letter for alogliptin NDA for type 2 diabetes |
30 Jun 09, 03:48 |
|
| Takeda Pharmaceutical Company Limited (Takeda) announced that Takeda Global Research and Development Center, Inc, a wholly-owned United States (US) subsidiary received on June 26 (US time) a complete response letter from the US Food and Drug Administration (FDA) regarding the company's New Drug Application (NDA) for alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under ... |
| more |
|
